Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deymeer, F.
Right arrow Articles by Saruhan-Direskeneli, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deymeer, F.
Right arrow Articles by Saruhan-Direskeneli, G.
Related Collections
Right arrow All Immunology
Right arrow Autoimmune diseases
Right arrow Myasthenia
Right arrowRelated Article
NEUROLOGY 2007;68:609-611
© 2007 American Academy of Neurology

Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis

F. Deymeer, MD, MS (Epid), O. Gungor-Tuncer, MD, V. Yilmaz, MS, Y. Parman, MD, P. Serdaroglu, MD, C. Ozdemir, MD, A. Vincent, MBBS, MSc, FRCPath, FMedSci and G. Saruhan-Direskeneli, MD

From the Departments of Neurology (F.D., O.G.-T., Y.P., P.S., C.O.) and Physiology (V.Y., G.S.-D.), Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey; and Neurosciences Group (A.V.), Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.

Address correspondence and reprint requests to Dr. Feza Deymeer, Department of Neurology, Istanbul University, Istanbul Medical Faculty, Capa, 34390 Istanbul, Turkey; e-mail: deymeer{at}tnn.net

We compared 65 anti-acetylcholine receptor (AChR)-negative myasthenia gravis (MG) patients, including 32 anti-muscle-specific tyrosine kinase (MuSK)-positive (49%) and 33 anti-MuSK-negative (seronegative) (51%) patients, with 161 anti-AChR-positive MG patients. The anti-MuSK-positive group had a higher frequency of bulbar involvement and respiratory crises. The seronegative group was in between the anti-MuSK positive and the anti-AChR positive groups, being closer to the latter, with regard to the severity of the disease. At the end of follow-up, the outcome of the anti-MuSK-positive patients was not different from that of the anti-AChR-positive patients, although their maintenance corticosteroid dose was higher. The seronegative patients had better outcome than the other two groups.

This work was supported by the Istanbul University Research Fund.

Disclosure: The authors report no conflicts of interest.

Received March 10, 2006. Accepted in final form November 1, 2006.


Related Article

February 20 Highlights
Neurology 2007 68: 540-541. [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.